CRIS
Closed
Curis Inc
2.15
-0.17 (-7.33%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.32
Day's Range: 2.09 - 2.4821
Send
sign up or login to leave a comment!
When Written:
0.596
Curis Inc. is a biotechnology company that develops and commercializes innovative drug candidates for the treatment of cancer. The company's lead product candidate is called CA-4948, which is a small molecule inhibitor of the protein IRAK4. This protein plays a critical role in the activation of the immune system and the development of cancer.
Curis was founded in 2000 and is headquartered in Lexington, Massachusetts. The company has a team of experienced scientists and researchers who work on the discovery and development of new drugs. Curis also has partnerships with other companies and research institutions to advance its drug candidates.
In addition to CA-4948, Curis has several other drug candidates in development, including CA-327, which is a small molecule inhibitor of the protein CK1α, and CA-170, which is a small molecule inhibitor of the immune checkpoint proteins PD-L1 and VISTA. The company's goal is to develop novel therapies that can improve the lives of cancer patients.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Curis was founded in 2000 and is headquartered in Lexington, Massachusetts. The company has a team of experienced scientists and researchers who work on the discovery and development of new drugs. Curis also has partnerships with other companies and research institutions to advance its drug candidates.
In addition to CA-4948, Curis has several other drug candidates in development, including CA-327, which is a small molecule inhibitor of the protein CK1α, and CA-170, which is a small molecule inhibitor of the immune checkpoint proteins PD-L1 and VISTA. The company's goal is to develop novel therapies that can improve the lives of cancer patients.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








